AMPKα loss promotes KRAS-mediated lung tumorigenesis.

AMP-Activated Protein Kinases / metabolism Animals Carcinogenesis Disease Models, Animal Humans Lung Neoplasms / genetics Mice Proto-Oncogene Proteins p21(ras) / genetics

Journal

Cell death and differentiation
ISSN: 1476-5403
Titre abrégé: Cell Death Differ
Pays: England
ID NLM: 9437445

Informations de publication

Date de publication:
09 2021
Historique:
received: 17 07 2020
accepted: 25 03 2021
revised: 22 03 2021
pubmed: 28 5 2021
medline: 22 3 2022
entrez: 27 5 2021
Statut: ppublish

Résumé

AMP-activated protein kinase (AMPK) is a critical sensor of energy status that coordinates cell growth with energy balance. In non-small cell lung cancer (NSCLC) the role of AMPKα is controversial and its contribution to lung carcinogenesis is not well-defined. Furthermore, it remains largely unknown whether long non-coding RNAs (lncRNAs) are involved in the regulation of AMPK-mediated pathways. Here, we found that loss of AMPKα in combination with activation of mutant KRAS

Identifiants

DOI: 10.1038/s41418-021-00777-0 PMID: 34040167 PMC: PMC8408205
pubmed: 34040167
doi: 10.1038/s41418-021-00777-0
pii: 10.1038/s41418-021-00777-0
pmc: PMC8408205
doi:

Substances chimiques

AMP-Activated Protein Kinases EC 2.7.11.31
Proto-Oncogene Proteins p21(ras) EC 3.6.5.2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2673-2689

Subventions

Organisme : Cancer Research UK (CRUK)
ID : C5759/A20971

Informations de copyright

© 2021. The Author(s), under exclusive licence to ADMC Associazione Differenziamento e Morte Cellulare.

Références

Moran C. Importance of molecular features of non-small cell lung cancer for choice of treatment. Am J Pathol. 2011;178:1940–8.
pubmed: 21514411 pmcid: 3081153 doi: 10.1016/j.ajpath.2010.12.057
Yang H, Liang SQ, Schmid RA, Peng RW. New horizons in KRAS-mutant lung cancer: dawn after darkness. Front Oncol. 2019;9:1–13.
doi: 10.3389/fonc.2019.00953
Pupo E, Avanzato D, Middonti E, Bussolino F, Lanzetti L. KRAS-driven metabolic rewiring reveals novel actionable targets in cancer. Front Oncol. 2019;9:1–9.
doi: 10.3389/fonc.2019.00848
Yun J, Rago C, Cheong I, Pagliarini R, Angenendt P, Rajagopalan H, et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science. 2009;325:1555–9.
pubmed: 19661383 pmcid: 2820374 doi: 10.1126/science.1174229
Faubert B, Vincent EE, Poffenberger MC, Jones RG. The AMP-activated protein kinase (AMPK) and cancer: Many faces of a metabolic regulator. Cancer Lett. 2015;356:165–70.
pubmed: 24486219 doi: 10.1016/j.canlet.2014.01.018
Carling D, Thornton C, Woods A, Sanders MJ. AMP-activated protein kinase: new regulation, new roles? Biochem J. 2012;445:11–27.
pubmed: 22702974 doi: 10.1042/BJ20120546
Hardie DG. AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes Dev. 2011;25:1895–908.
pubmed: 21937710 pmcid: 3185962 doi: 10.1101/gad.17420111
Ross FA, MacKintosh C, Hardie DG. AMP-activated protein kinase: a cellular energy sensor that comes in 12 flavours. FEBS J. 2016;283:2987–3001.
pubmed: 26934201 pmcid: 4995730 doi: 10.1111/febs.13698
Hawley SA, Boudeau J, Reid JL, Mustard KJ, Udd L, Makela TP, et al. Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J Biol. 2003;2:28.
pubmed: 14511394 pmcid: 333410 doi: 10.1186/1475-4924-2-28
Woods A, Johnstone SR, Dickerson K, Leiper FC, Fryer LGD, Neumann D, et al. LKB1 Is the Upstream Kinase in the AMP-Activated Protein Kinase Cascade. Curr Biol. 2003;13:2004–8.
pubmed: 14614828 doi: 10.1016/j.cub.2003.10.031
Shaw RJ, Kosmatka M, Bardeesy N, Hurley RL, Witters LA, DePinho RA, et al. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci USA. 2004;101:3329–35.
pubmed: 14985505 pmcid: 373461 doi: 10.1073/pnas.0308061100
Skoulidis F, Byers LA, Diao L, Papadimitrakopoulou VA, Tong P, Izzo J, et al. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov. 2015;5:861–78.
doi: 10.1158/2159-8290.CD-14-1236
Hawley SA, Pan DA, Mustard KJ, Ross L, Bain J, Edelman AM, et al. Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. Cell Metab. 2005;2:9–19.
pubmed: 16054095 doi: 10.1016/j.cmet.2005.05.009
Woods A, Dickerson K, Heath R, Hong S-P, Momcilovic M, Johnstone SR, et al. Ca2+/calmodulin-dependent protein kinase kinase-beta acts upstream of AMP-activated protein kinase in mammalian cells. Cell Metab. 2005;2:21–33.
pubmed: 16054096 doi: 10.1016/j.cmet.2005.06.005
Murray CW, Brady JJ, Tsai MK, Li C, Winters IP, Tang R, et al. An LKB1–SIK axis suppresses lung tumor growth and controls differentiation. Cancer Disco. 2019;9:1590–605.
doi: 10.1158/2159-8290.CD-18-1237
Jeon S-M, Chandel NS, Hay N. AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature. 2012;485:661–5.
pubmed: 22660331 pmcid: 3607316 doi: 10.1038/nature11066
Saha M, Kumar S, Bukhari S, Balaji SA, Kumar P, Hindupur SK, et al. AMPK-AKT double negative feedback loop in breast cancer cells regulates their adaptation to matrix deprivation. Cancer Res. 2018;78:1497–510.
pubmed: 29339542 pmcid: 6033311 doi: 10.1158/0008-5472.CAN-17-2090
Fang Y, Fullwood MJ. Roles, functions, and mechanisms of long non-coding RNAs in cancer. Genomics Proteom Bioinforma. 2016;14:42–54.
doi: 10.1016/j.gpb.2015.09.006
Schmitt AM, Chang HY. Long noncoding RNAs in cancer pathways. Cancer Cell. 2016;29:452–63.
pubmed: 27070700 pmcid: 4831138 doi: 10.1016/j.ccell.2016.03.010
Sun H, Huang Z, Sheng W, Xu MD. Emerging roles of long non-coding RNAs in tumor metabolism. J Hematol Oncol. 2018;11:1–16.
doi: 10.1186/s13045-018-0648-7
Howell JJ, Hellberg K, Turner M, Talbott G, Kolar MJ, Ross DS, et al. Metformin Inhibits Hepatic mTORC1 Signaling via Dose-Dependent Mechanisms Involving AMPK and the TSC Complex. Cell Metab. 2017;25:463–71.
pubmed: 28089566 pmcid: 5299044 doi: 10.1016/j.cmet.2016.12.009
Pfeifer A, Brandon EP, Kootstra N, Gage FH, Verma IM. Delivery of the Cre recombinase by a self-deleting lentiviral vector: Efficient gene targeting in vivo. Proc Natl Acad Sci USA. 2001;98:11450–5.
pubmed: 11553794 pmcid: 58750 doi: 10.1073/pnas.201415498
Shi L, Magee P, Fassan M, Sahoo S, Leong HS, Lee D, et al. A KRAS-responsive long non-coding RNA controls microRNA processing. Nat Commun. 2021;12:1–19. https://doi.org/10.1038/s41467-021-22337-3 .
Yamaguchi T, Kakefuda R, Tajima N, Sowa Y, Sakai T. Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo. Int J Oncol. 2011;39:23–31.
pubmed: 21523318
Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108(Oct):1167–74.
pubmed: 11602624 pmcid: 209533 doi: 10.1172/JCI13505
Cool B, Zinker B, Chiou W, Kifle L, Cao N, Perham M, et al. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab. 2006;3(Jun):403–16.
pubmed: 16753576 doi: 10.1016/j.cmet.2006.05.005
Shaw RJ. LKB1 and AMP-activated protein kinase control of mTOR signalling and growth. Acta Physiol (Oxf). 2009;196(May):65–80.
doi: 10.1111/j.1748-1716.2009.01972.x
Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, et al. AMPK phosphorylation of Raptor mediates a metabolic checkpoint. Mol Cell. 2008;30:214–26.
pubmed: 18439900 pmcid: 2674027 doi: 10.1016/j.molcel.2008.03.003
Inoki K, Zhu T, Guan K-L. TSC2 mediates cellular energy response to control cell growth and survival. Cell. 2003;115:577–90.
pubmed: 14651849 doi: 10.1016/S0092-8674(03)00929-2
Kurreck J, Wyszko E, Gillen C, Erdmann VA. Design of antisense oligonucleotides stabilized by locked nucleic acids. Nucleic Acids Res. 2002;30:1911–8.
pubmed: 11972327 pmcid: 113840 doi: 10.1093/nar/30.9.1911
McCleland ML, Adler AS, Deming L, Cosino E, Lee L, Blackwood EM, et al. Lactate dehydrogenase B is required for the growth of KRAS-dependent lung adenocarcinomas. Clin Cancer Res. 2013;19:773–84.
pubmed: 23224736 doi: 10.1158/1078-0432.CCR-12-2638
Markert CL, Shaklee JB, Whitt GS. Evolution of a gene. Multiple genes for LDH isozymes provide a model of the evolution of gene structure, function, and regulation. Science. 1975;189:102–14.
pubmed: 1138367 doi: 10.1126/science.1138367
Porporato PE, Dhup S, Dadhich RK, Copetti T, Sonveaux P. Anticancer targets in the glycolytic metabolism of tumors: A comprehensive review. Front Pharm. 2011;2:1–18.
doi: 10.3389/fphar.2011.00049
Jeon S-M, Hay N. The double-edged sword of AMPK signaling in cancer and its therapeutic implications. Arch Pharm Res. 2015;38:346–57.
pubmed: 25575627 pmcid: 5789788 doi: 10.1007/s12272-015-0549-z
Eichner LJ, Brun SN, Herzig S, Young NP, Curtis SD, Shackelford DB, et al. Genetic analysis reveals AMPK is required to support tumor growth in murine Kras-dependent lung cancer models. Cell Metab. 2019;29:285–302.
pubmed: 30415923 doi: 10.1016/j.cmet.2018.10.005
Jackson EL, Olive KP, Tuveson DA, Bronson R, Crowley D, Brown M, et al. The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res. 2005;65:10280–8.
pubmed: 16288016 doi: 10.1158/0008-5472.CAN-05-2193
Sutherland KD, Song J-Y, Kwon MC, Proost N, Zevenhoven J, Berns A. Multiple cells-of-origin of mutant K-Ras–induced mouse lung adenocarcinoma. Proc Natl Acad Sci. 2014;111:4952–7.
pubmed: 24586047 pmcid: 3977239 doi: 10.1073/pnas.1319963111
Gera JF, Mellinghoff IK, Shi Y, Rettig MB, Tran C, Hsu JH, et al. AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem. 2004;279:2737–46.
pubmed: 14576155 doi: 10.1074/jbc.M309999200
Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer’s Achilles’ Heel. Cancer Cell. 2008;13:472–82.
pubmed: 18538731 doi: 10.1016/j.ccr.2008.05.005
Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, Montoya R, et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 2001;15:3243–8.
pubmed: 11751630 pmcid: 312845 doi: 10.1101/gad.943001
DuPage M, Dooley AL, Jacks T. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat Protoc. 2009;4:1064–72.
pubmed: 19561589 pmcid: 2757265 doi: 10.1038/nprot.2009.95
Stewart SA, Dykxhoorn DM, Palliser D, Mizuno H, Yu EY, An DS, et al. Lentivirus-delivered stable gene silencing by RNAi in primary cells. Rna. 2003;9:493–501.
pubmed: 12649500 pmcid: 1370415 doi: 10.1261/rna.2192803
Shi L, Middleton J, Jeon YJ, Magee P, Veneziano D, Laganà A, et al. KRAS induces lung tumorigenesis through microRNAs modulation. Cell Death Dis. 2018;9:1–15.
doi: 10.1038/s41419-017-0243-9
Egan DF, Shackelford DB, Mihaylova MM, Gelino SR, Rebecca A, Mair W, et al. Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. Science. 2011;331:456–61.
pubmed: 21205641 doi: 10.1126/science.1196371
Liao Y, Smyth GK, Shi W. The subread aligner: fast, accurate and scalable read mapping by seed-and-vote. Nucleic Acids Res. 2013;41:e108.
pubmed: 23558742 pmcid: 3664803 doi: 10.1093/nar/gkt214
Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.
pubmed: 25516281 pmcid: 4302049 doi: 10.1186/s13059-014-0550-8

Auteurs

Manuela La Montagna (M)

Transcriptional Networks in Lung Cancer Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK.
Cancer Research UK Lung Cancer Centre of Excellence, at Manchester and University College London, London, UK.
ORCID: 0000-0001-7568-8207

Lei Shi (L)

Transcriptional Networks in Lung Cancer Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK.
Cancer Research UK Lung Cancer Centre of Excellence, at Manchester and University College London, London, UK.

Peter Magee (P)

Transcriptional Networks in Lung Cancer Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK.
Cancer Research UK Lung Cancer Centre of Excellence, at Manchester and University College London, London, UK.

Sudhakar Sahoo (S)

Computational Biology Support, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK.

Matteo Fassan (M)

Department of Medicine, Surgical Pathology & Cytopathology Unit, University of Padua, Padua, Italy. matteo.fassan@unipd.it.

Michela Garofalo (M)

Transcriptional Networks in Lung Cancer Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK. michelagarofalo1@gmail.com.
Cancer Research UK Lung Cancer Centre of Excellence, at Manchester and University College London, London, UK. michelagarofalo1@gmail.com.
ORCID: 0000-0002-1741-0415

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines et peptides de signalisation intracellulaire › Protein-Serine-Threonine Kinases › AMP-Activated Protein Kinases › AMPKα loss promotes KRAS-mediated lung tumorigenesis.
questionsmedicales.fr › Eucaryotes › Animaux › AMPKα loss promotes KRAS-mediated lung tumorigenesis.
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Processus néoplasiques › Carcinogenèse › AMPKα loss promotes KRAS-mediated lung tumorigenesis.
questionsmedicales.fr › Techniques d'investigation › Modèles théoriques › Modèles biologiques › Modèles animaux de maladie humaine › AMPKα loss promotes KRAS-mediated lung tumorigenesis.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › AMPKα loss promotes KRAS-mediated lung tumorigenesis.
questionsmedicales.fr › Maladies de l'appareil respiratoire › Tumeurs de l'appareil respiratoire › Tumeurs du poumon › AMPKα loss promotes KRAS-mediated lung tumorigenesis.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › AMPKα loss promotes KRAS-mediated lung tumorigenesis.
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines tumorales › Protéines oncogènes › Protéines proto-oncogènes › Protéines proto-oncogènes p21(ras) › AMPKα loss promotes KRAS-mediated lung tumorigenesis.